Recovery of menstrual function in patients with placenta accreta spectrum disorders
- Authors: Marchenko R.N.1, Kukarskaya I.I.1
-
Affiliations:
- Tyumen Regional Perinatal Center
- Issue: No 7 (2020)
- Pages: 100-104
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248883
- DOI: https://doi.org/10.18565/aig.2020.7.100-104
- ID: 248883
Cite item
Open Access
Access granted
Abstract
Aim. To investigate the menstrual function recovery time in patients with placenta accreta spectrum disorders. Material and methods. The study prospectively analyzed 147 medical records of pregnant women with abnormal placental implantation, who underwent different methods of intraoperative hemostasis. Uterine artery embolization, hysterectomy, and surgical hemostasis without hysterectomy were performed in groups I1, I2, and I3, respectively. The study evaluated postoperative blood loss, hormonal levels, and menstrual function recovery time. Statistical analysis was performed using the Statistica 6 software. Results. During the three months of the study, menstrual cycle returned in 67.9% and 10% of patients in groups I} and I3, respectively. The fastest return to normal levels of hormones was observed in patients of group I. Conclusion. The embolization of the uterine arteries is an effective organ-sparing technique that contributes to the rapid resumption of menstrual function.
Full Text
About the authors
Roman N. Marchenko
Tyumen Regional Perinatal Center
Email: vrach08@rambler.ru
graduate student of the Department of Obstetrics, Gynecology and Intensive Care with a course of clinical and laboratory diagnostics
Irina I. Kukarskaya
Tyumen Regional Perinatal Center
Email: kukarskay@mail.ru
MD, professor of the Department of Obstetrics, CTNC and Reanimatology with a course of clinical laboratory diagnostics
References
- Курцер М.А., Бреслав И.Ю., Григорян А.М., Кутакова Ю.Ю., Черепнина А.Л., Штабницкий А.М. Актуальные вопросы лечения послеродовых кровотечений в акушерстве. Медицинский алфавит. 2018; 1(9): 14-7.
- Зверев Д.А., Приворотский В.В., Зазерская И.Е., Доброскок И.Н. Методика временной эндоваскулярной эмболизации маточных артерий при оперативном родоразрешении. Евразийский союз ученых. 2014; 8-6: 24-5.
- Виницкий А.А., Шмаков Р.Г. Современные представления об этиопатогенезе врастания плаценты и перспективы его прогнозирования молекулярными методами диагностики. Акушерство и гинекология. 2017; 2: 5-10. [Vinitsky A.A., Shmakov R.G. Modern ideas about the etiopathogenesis of abnormal placental implantation and the prospects for its prediction by molecular diagnostic methods. Obstetrics and gynecology. 2017; 2: 5-10. (in Russian)]. https://dx.doi.org/10.18565/ aig.2017.2.5-10.
- Хасанов А.А. Диагностика, профилактика и органосохраняющие методы родоразрешения беременных с врастанием плаценты. Казанский медицинский журнал. 2016; 97(4): 477-85. [Khasanov A.A. Diagnosis, prevention and organ-preserving method of delivery in pregnant women with placenta accreta. Kazan medical journal 2016; 97(4): 477-85. (in Russian)]. https://dx.doi.org/10.17750/KMJ2015-477.
- Carusi D.A. The placenta accreta spectrum: epidemiology and risk factors. Clin. Obstet. Gynecol. 2018; 61(4): 733-42. https://dx.doi.org/10.1097/ GRF.0000000000000391.
- Sun W., Yu L., Liu S., Chen Y., Chen J., Wen S.W., Chen D. Comparison of maternal and neonatal outcomes for patients with placenta accreta spectrum between online-to-offline management model with standard care model. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018; 222: 161-5. https://dx.doi.org/10.1016/j. ejogrb.2018.01.035.
- Reda A. Comments on: conservative surgical treatment of a case of placenta accreta. Rev. Bras. Ginecol. Obstet. 2018; 40(10): 654-5. https://dx.doi. org/10.1055/s-0038-1675221.
- Long Y., Chen Y., Fu X.Q., Yang F., Chen Z.W., Mo G.L. et al. Research on the expression of MRNA-518b in the pathogenesis of placenta accreta. Eur. Rev. Med. Pharmacol. Sci. 2019; 23(1): 23-8. https://dx.doi.org/10.26355/ eurrev_201901_16743.
- Creanga A.A., Bateman B.T., Butwick A.J., Raleigh L., Maeda A., Kuklina E., Callaghan W.M. Morbidity associated with cesarean delivery in the United States: is placenta accreta an increasingly important contributor? Am. J. Obstet. Gynecol. 2015; 213(3): 384. e1-11. https://dx.doi.org/10.1016/ j.ajog.2015.05.002.
- Maymon S., Maymon R., Bornstein J., Tovbin J., Melcer Y., Frank Wolf M. Comparison of two approaches for placenta accreta: uterine preservation versus cesarean hysterectomy. Harefuah. 2018; 157(11): 696-700.
- Farasatinasab M., Moghaddas A., Dashti-Khadivaki S., Raoofi Z., Nasiripour S. Management of abnormal placenta implantation with methotrexate: A review of published data. Gynecol. Obstet. Invest. 2016; 81(6): 481-96. https://dx.doi. org/10.1159/000447556.
- Lopez-Jimenez F., Pniagua D., Lamas G.A. La interpretacion de los ensayos clinicos negatovos. Rev. Invest. Clin. 1998; 50(5): 435-40.
- Олейникова О.Н. Оценка эффективности эмболизации маточных артерий при маточных кровотечениях различной этиологии. АГ-Инфо. 2009; 2: 38-42.
- Шадрин Р.В., Шумова М.А., Кулик В.В., Назарян Г.С. Органосохраняющие операции у беременных с врастанием плаценты: наш опыт. Научный вестник здравоохранения Кубани. 2017; 2: 108-16.
- Дикун Т.В.,Брагинец А.С., Терпелова А.С.,Кузьмич Н.В.,Петрашевский А.И., Крицкий Д.В., Буцанец А.В., Устинович О.Ю. Эмболизация маточных артерий как метод лечения миомы матки. Молодой ученый. 2018; 16: 24-5.
Supplementary files
